The OVERALL OBJECTIVE of this renewal is to define the mechanisms, consequences and pathologic outcomes of cholangiocyte senescence in the syndrome of primary sclerosing cholangitis (PSC). While the cholangiocyte plays an integral role in the cholangiopathies, including PSC, how cholangiocyte signaling contributes to the initiation and progression of PSC is unknown. Recent evidence from our lab supported by this grant indicates that: (i) cholangiocytes express pathogen recognition receptors (PRRs) including toll-like receptors (TLRs);(ii) upon pathogen recognition, cholangiocytes are activated to initiate downstream signaling pathways involving Nuclear Factor Kappa B (NF?B), the p21 Ras isoform, Mitogen Activated Protein Kinase (MAPK) and post-transcriptional regulatory networks involving microRNAs (miRNA), including let-7i;(iii) cultured human cholangiocytes, in response to potentially injurious microbial molecules, develop a senescent phenotype with characteristics of stress-induced senescence;(iv) these senescent cholangiocytes transition to a senescence-associated secretory phenotype (SASP) characterized by excessive expression and release of proinflammatory mediators, including IL6 and IL8;and (v) liver tissue from patients with PSC exhibits an increased proportion of cholangiocytes with the senescent and SASP phenotype compared to normal and disease control tissue. Thus, our data support the original CENTRAL HYPOTHESIS that persistent exogenous insult induces TLR-dependent activation of Ras/MAPK promoting let-7i miRNA - dependent cholangiocyte senescence and SASP, a phenotype that contributes to the fibroinflammatory features of PSC. We will test this hypothesis by using novel in vitro biochemical and molecular techniques and in vivo animal models to dissect the mechanisms, consequences and pathologic outcomes of cholangiocyte senescence and SASP-induced secretion of proinflammatory mediators. Our proposal has three integrated SPECIFIC AIMS. FIRST, we will test the hypothesis that bacterial derived molecules in bile induce cholangiocyte senescence through Ras/MAPK activation and let-7i dependent epigenetic silencing of E2F- responsive cell cycle genes. SECOND, we will test the hypothesis that cholangiocytes transition to SASP by IL6- induced activation of C/EBP? and promote paracrine-mediated cholangiocyte senescence and stellate cell activation via hypersecretion of proinflammatory mediators. FINALLY, we will test the hypothesis that, in the Mdr2-deficient mouse model of PSC, cholangiocyte senescence contributes to the characteristic inflammation while genetic reversal or inhibition of cholangiocyte senescence and SASP will ameliorate the biliary disease. Results from our innovative experiments will substantially clarify the signaling mechanisms by which potentially injurious biliary components cause cholangiocyte senescence and SASP in PSC, and will provide novel information that could impact our ability to slow progression of this incurable disease.

Public Health Relevance

This application examines the mechanisms, consequences and pathologic outcomes of cholangiocyte senescence in the syndrome of primary sclerosing cholangitis (PSC), an uncommon, progressive liver disease for which no effective therapy exists except liver transplant. If successful, the results of our studies could lead to new and potentiall effective treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK057993-11
Application #
8574183
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Sherker, Averell H
Project Start
2000-04-01
Project End
2018-06-30
Budget Start
2013-07-15
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$345,825
Indirect Cost
$128,325
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Tabibian, James H; Varghese, Cyril; LaRusso, Nicholas F et al. (2016) The enteric microbiome in hepatobiliary health and disease. Liver Int 36:480-7
Eaton, John E; Dzyubak, Bogdan; Venkatesh, Sudhakar K et al. (2016) Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol 31:1184-90
Hirsova, Petra; Ibrahim, Samar H; Verma, Vikas K et al. (2016) Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology 64:2219-2233
Tabibian, James H; O'Hara, Steven P; Trussoni, Christy E et al. (2016) Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 63:185-96
Gradilone, Sergio A; Lorenzo Pisarellob, María J; LaRussob, Nicholas F (2015) Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma. Curr Drug Targets :
Lazaridis, Konstantinos N; LaRusso, Nicholas F (2015) The Cholangiopathies. Mayo Clin Proc 90:791-800
Gradilone, Sergio A; O'Hara, Steven P; Masyuk, Tetyana V et al. (2015) MicroRNAs and benign biliary tract diseases. Semin Liver Dis 35:26-35
Masyuk, Tatyana V; Masyuk, Anatoliy I; LaRusso, Nicholas F (2015) TGR5 in the Cholangiociliopathies. Dig Dis 33:420-5
Zhu, Yi; Tchkonia, Tamara; Pirtskhalava, Tamar et al. (2015) The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14:644-58
Tabibian, James H; Trussoni, Christy E; O'Hara, Steven P et al. (2014) Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Lab Invest 94:1126-33

Showing the most recent 10 out of 43 publications